This Article Full Text Full Text (PDF) All Versions of this Article: 40/1/147    most recent STROKEAHA.108.518621v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Mosca, L. Articles by Kornitzer, M. Search for Related Content PubMed PubMed Citation Articles by Mosca, L. Articles by Kornitzer, M. Related Collections Deep vein thrombosis Acute Cerebral Infarction Acute Stroke Syndromes Risk Factors for Stroke

(Stroke. 2009;40:147.)
© 2009 American Heart Association, Inc.

Original Contributions

Effect of Raloxifene on Stroke and Venous Thromboembolism According to Subgroups in Postmenopausal Women at Increased Risk of Coronary Heart Disease

Lori Mosca, MD, PhD; Deborah Grady, MD, MPH; Elizabeth Barrett-Connor, MD; Peter Collins, MD; Nanette Wenger, MD; Beth L. Abramson, MD; Annlia Paganini-Hill, PhD; Mary Jane Geiger, MD, PhD; Sherie A. Dowsett, PhD; Messan Amewou-Atisso, PhD Marcel Kornitzer, MD

From Columbia University (L.M.), New York, NY; the University of California, San Francisco (D.G.), San Francisco, Calif; the University of California–San Diego (E.B.-C.), La Jolla, Calif; Royal Brompton Hospital and Imperial College (P.C.), London, UK; Emory University (N.W.), Atlanta, Ga; the University of Toronto (B.L.A.), Toronto, Ontario, Canada; Keck School of Medicine (A.P.-H.), University of Southern California, Los Angeles, Calif; Eli Lilly and Company (M.J.G., S.A.D., M.A.-A.), Indianapolis, Ind; and Brussels Free University (M.K.), Brussels, Belgium.

Correspondence to Lori Mosca, Director, Preventive Cardiology, New York–Presbyterian Hospital, 601 West 168th Street, #43, New York, NY 10032. E-mail ljm10{at}columbia.edu; lmr2@columbia.edu

Background and Purpose— Raloxifene, a selective estrogen receptor modulator, reduces risk of invasive breast cancer and osteoporosis, but the effect on risk for stroke and venous thromboembolism in different patient subgroups is not established. The purpose of this analysis was to evaluate the effect of raloxifene on the incidence of all strokes, stroke deaths, and venous thromboembolic events according to participant subgroups.

Methods— This was a secondary end point analysis of an international, randomized, placebo-controlled clinical trial of 10 101 postmenopausal women with or at increased risk of coronary heart disease followed a median of 5.6 years. Strokes, venous thromboembolic events, and deaths were adjudicated by expert centralized committees. Strokes were categorized as ischemic, hemorrhagic, or undetermined and venous thromboembolic events were subclassified.

Results— The incidences of all strokes did not differ between raloxifene (incidence rate per 100 woman-years=0.95) and placebo (incidence rate=0.86) treatment groups (P=0.30). In women assigned raloxifene versus placebo, there was a higher incidence of fatal strokes (incidence rates=0.22 and 0.15, respectively, P=0.0499) and venous thromboembolic events (incidence rates=0.39 and 0.27, respectively, P=0.02). No significant subgroup interactions were found except that there was a higher incidence of stroke associated with raloxifene use among current smokers.

Conclusions— In postmenopausal women at increased risk for coronary events, the incidences of venous thromboembolism and fatal stroke but not all strokes were higher in those assigned raloxifene versus placebo. Raloxifene’s effect did not differ across subgroups, except that the risk of stroke differed by smoking status. Treatment decisions about raloxifene should be based on a balance of projected absolute risks and benefits.

Key Words: clinical trial • stroke • venous thromboembolism